“One woman dies of cervical cancer every two minutes…Each one is a tragedy, and we can prevent it.”
The use of radiation therapy remains an essential component of treatment for cervical cancer to achieve a cure.
The use of an SBRT boost with the CyberKnife System has been shown to provide excellent sparing of nearby organs at risk (OARs) with optimum target volume coverage.
Importantly, it can be used as an alternative for patients unable to undergo intra-cavity brachytherapy boost, increasing treatment options for patients.
Treatment Guidelines:
Post-operative Radiation Therapy:
Cervical cancer treatment can include a combination of surgery, chemotherapy and radiation therapy depending on the size, type, and location of the tumor as well as a person’s overall health.
There is strong evidence supporting the use of radiation therapy with or without chemotherapy in both definitive and post operative settings.
In 2020, the American Society for Radiation Oncology (ASTRO) created a task force to provide recommendations for the appropriate techniques of radiation therapy in the treatment of non-metastatic cervical cancer.
The guidelines recommend post-operative radiation therapy for patients with intermediate risk factors and chemo-radiation for those with high risk factors.
In the last two decades, there have been notable advances in surgical procedures, external radiation therapy techniques, brachytherapy and chemotherapy regimens.
Radiation is an integral part of the management of locally advanced disease whether as an adjuvant treatment after surgery or as a primary curative treatment.
Image-guided Radiation Therapy
Intensity-modulated radiation therapy (IMRT) is the recommended radiation therapy technique for external beam radiation therapy (EBRT) for all women to allow dose escalation and reduce acute and late toxicity.
IMRT minimizes dose to the bladder, rectum, bowel, and bone marrow which can potentially reduce side effects and allow patients to experience a better quality of life after treatment.
Management of tumor motion with the use of image guidance is of the upmost importance in IMRT to ensure treatment accuracy.
EBRT is usually followed by an intra-cavity brachytherapy boost to the primary site, which has been shown to be an essential part of definitive management.
Using image guided brachytherapy (IGBT) serves to deliver a high radiation dose internally to the cervix while helping minimize the dose to the surrounding anatomy.
ESTRO and ASTRO Guidelines
The European Society of Gynecological Oncology, European Society of Radiotherapy and Oncology, and the European Society of Pathology (ESGO-ESTRO-ESP) published guidelines for the treatment of cervical cancer in 2018, which closely align with the ASTRO 2020 guidelines.
These guidelines state that MRI image-guided brachytherapy is the preferable choice, recommended as an integral component of definitive radiation therapy as it has consistently demonstrated improved outcomes.
A large study called the EMBRACE study provided strong evidence of long-term local control in locally advanced cervical cancer using chemo-radiotherapy and MRI-based image-guided adaptive brachytherapy (IGABT).
However There Are Challenges with Brachytherapy:
In the real-world there has been declining use of brachytherapy. For some countries like Germany it can be difficult to find adequate brachytherapy with high tech brachytherapy equipment that meet the requirements of GEC-ESTRO recommendations, making access limited.
Another study revealed a decline in brachytherapy utilization in the U.S that was strongly influenced by federal reimbursement policies adopting the use of IMRT boost as an alternative to brachytherapy for cervical cancer.
Brachytherapy is technically demanding and resource intensive, therefore it became more feasible to choose IMRT as an alternative than referring to another facility.
Additional challenges include unfavorable patient anatomy, difficulties in placing a Smit sleeve or pre-existing medical conditions that preclude the use of a brachytherapy boost, the presence of asymmetric tumors where a satisfying dose coverage cannot be achieved with the brachytherapy equipment available, and patient refusal of the procedure.
For these situations, a targeted external stereotactic body radiotherapy (SBRT) boost can be considered.
What is the Alternative Option for Cervical Cancer Patients?
Brachytherapy vs CyberKnife:
Several studies have examined the safety and efficacy of delivering an SBRT boost with the CyberKnife® System to the cervix after EBRT in patients unable to receive treatment with brachytherapy.
The CyberKnife System has been shown to allow more precise targeting and delivery of radiation to the cervix compared to conventional linac-based radiation.
This allows dose escalation to the cervix that demonstrates a comparable dose to a brachytherapy boost.
CyberKnife SBRT emulates brachytherapy by having multiple non-coplanar beams intersecting the cervix, delivering a high therapeutic dose while minimizing dose to normal anatomy.
It provides steep dose gradients, offering excellent coverage of complex target volumes, with the added advantage of performing real-time motion tracking where the dynamic robotic delivery automatically changes the position of the linear accelerator to correct for rotational and translational movement of the patient and the cervix during treatment.
This automatic motion correction capability is imperative to ensure the accurate delivery of high-dose radiation.
CyberKnife System studies have demonstrated excellent local control with no increase in toxicities after EBRT.
While direct comparisons aren’t possible, the overall survival rates achieved using CyberKnife SBRT boost have been similar to those published in the brachytherapy EMBRACE trial.
Another study compared CyberKnife and brachytherapy plans finding that the Cyberknife SBRT boost could result in significantly better target coverage, organ at risk (OARs) sparing and radiobiological effects compared to the brachytherapy plan.
Click On The Link To See Abby’s Story: https://youtu.be/tpDoEPQt__0
Abby shares her diagnosis and treatment journey. She was diagnosed with stage III cervical cancer and went on to have EBRT with chemotherapy followed by an SBRT boost delivered with the CyberKnife System.
Intra-cavity brachytherapy was not an option for Abby due to difficulties placing the Smit sleeve, a procedure required for internal radiation.
Treatment with the CyberKnife System was the best and only option available to her.
For more information, or a consultation contact the cancer experts at the Cyberknife Center of Miami – The Beam Of Life 305-279-2900.